PriceTargets.com logo

ImmunityBio - IBRX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.00
  • Forecasted Upside: 3.73%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.82 As of 04/24/2024 01:00 AM ET
▼ -0.67 (-12.20%)

This chart shows the closing price for IBRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmunityBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IBRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IBRX

Analyst Price Target is $5.00
▲ +3.73% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ImmunityBio in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 3.73% upside from the last price of $4.82.

This chart shows the closing price for IBRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in ImmunityBio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2024Piper SandlerBoost TargetNeutral ➝ Neutral$4.00 ➝ $5.00Low
5/12/2023Piper SandlerDowngradeOverweight ➝ Neutral$10.00 ➝ $4.00Low
8/3/2022Jefferies Financial GroupInitiated CoverageBuy$8.00Low
5/27/2022Piper SandlerLower Target$20.00 ➝ $10.00Low
4/7/2021Piper SandlerBoost TargetOverweight$18.00 ➝ $25.00Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/27/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 6 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 6 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

ImmunityBio logo
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
Read More

Today's Range

Now: $4.82
Low: $4.79
High: $5.72

50 Day Range

MA: $5.20
Low: $3.50
High: $6.17

52 Week Range

Now: $4.82
Low: $1.25
High: $6.93

Volume

7,916,720 shs

Average Volume

5,288,850 shs

Market Capitalization

$3.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunityBio?

The following Wall Street sell-side analysts have issued reports on ImmunityBio in the last twelve months: Piper Sandler.
View the latest analyst ratings for IBRX.

What is the current price target for ImmunityBio?

1 Wall Street analysts have set twelve-month price targets for ImmunityBio in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 3.7%. Piper Sandler has the highest price target set, predicting IBRX will reach $5.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $5.00 for ImmunityBio in the next year.
View the latest price targets for IBRX.

What is the current consensus analyst rating for ImmunityBio?

ImmunityBio currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IBRX, but not buy more shares or sell existing shares.
View the latest ratings for IBRX.

What other companies compete with ImmunityBio?

Other companies that are similar to ImmunityBio include Iovance Biotherapeutics, Immunovant, SpringWorks Therapeutics, Apogee Therapeutics and Arcellx. Learn More about companies similar to ImmunityBio.

How do I contact ImmunityBio's investor relations team?

ImmunityBio's physical mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The company's listed phone number is (858) 633-0300 and its investor relations email address is [email protected]. The official website for ImmunityBio is immunitybio.com. Learn More about contacing ImmunityBio investor relations.